Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blinatumomab in molecular relapse of AML with a t(8;21) translocation

Trial Profile

Blinatumomab in molecular relapse of AML with a t(8;21) translocation

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Pharmacodynamics
  • Acronyms BlinAML
  • Most Recent Events

    • 14 Jun 2024 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2024 Planned End Date changed from 7 Jul 2025 to 31 Dec 2025.
    • 16 Aug 2023 Status changed to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top